Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Broggini

Showing results (21-30 of 125) with videos related to

Pageof 13
Sort By:
BMC Cancer|October 25, 2018
Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cellsAlice Iezzi, Elisa Caiola, Arianna Scagliotti, et al.
Cell Cycle (Georgetown, Tex.)|August 25, 2004
Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53Laura Carrassa, Massimo Broggini, Eugenio Erba, et al.
Frontiers in Oncology|July 24, 2023
Editorial: Patient-derived tumor models for drug developmentHatim E Sabaawy, Massimo Broggini, Shiv K Gupta
Cancer Biology & Therapy|May 25, 2006
Questioning the oncogenic role of DeltaNp73alpha in different cell lines expressing p53 or notEleonora Marrazzo, Sergio Marchini, Sara Previdi, et al.
Cell Cycle (Georgetown, Tex.)|September 25, 2003
Characterization of the 5'flanking region of the human Chk1 gene: identification of E2F1 functional sitesLaura Carrassa, Massimo Broggini, Faina Vikhanskaya, et al.
Frontiers in Oncology|November 16, 2020
Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different MutationsMarika Colombo, Mirko Marabese, Giulia Vargiu, et al.
Oncotarget|June 23, 2014
Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cellsLaura Brunelli, Elisa Caiola, Mirko Marabese, et al.
American Journal of Cancer Research|January 8, 2021
Molecular determinants of response to PI3K/akt/mTOR and KRAS pathways inhibitors in NSCLC cell linesAlice Iezzi, Elisa Caiola, Marika Colombo, et al.
Cancer Management and Research|December 19, 2019
Lack of Efficacy: When Opioids Do Not Achieve Analgesia from the Beginning of Treatment in Cancer PatientsOscar Corli, Giovanna Damia, Francesca Galli, et al.
American Journal of Cancer Research|March 23, 2026
Erratum: Molecular determinants of response to PI3K/AKT/mTOR and KRAS pathways inhibitors in NSCLC cell linesAlice Iezzi, Elisa Caiola, Marika Colombo, et al.
Pageof 13

Showing results (21-30 of 125) with videos related to

Sort By:
Pageof 13
BMC Cancer|October 25, 2018
Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cellsAlice Iezzi, Elisa Caiola, Arianna Scagliotti, et al.
Cell Cycle (Georgetown, Tex.)|August 25, 2004
Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53Laura Carrassa, Massimo Broggini, Eugenio Erba, et al.
Frontiers in Oncology|July 24, 2023
Editorial: Patient-derived tumor models for drug developmentHatim E Sabaawy, Massimo Broggini, Shiv K Gupta
Cancer Biology & Therapy|May 25, 2006
Questioning the oncogenic role of DeltaNp73alpha in different cell lines expressing p53 or notEleonora Marrazzo, Sergio Marchini, Sara Previdi, et al.
Cell Cycle (Georgetown, Tex.)|September 25, 2003
Characterization of the 5'flanking region of the human Chk1 gene: identification of E2F1 functional sitesLaura Carrassa, Massimo Broggini, Faina Vikhanskaya, et al.
Frontiers in Oncology|November 16, 2020
Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different MutationsMarika Colombo, Mirko Marabese, Giulia Vargiu, et al.
Oncotarget|June 23, 2014
Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cellsLaura Brunelli, Elisa Caiola, Mirko Marabese, et al.
American Journal of Cancer Research|January 8, 2021
Molecular determinants of response to PI3K/akt/mTOR and KRAS pathways inhibitors in NSCLC cell linesAlice Iezzi, Elisa Caiola, Marika Colombo, et al.
Cancer Management and Research|December 19, 2019
Lack of Efficacy: When Opioids Do Not Achieve Analgesia from the Beginning of Treatment in Cancer PatientsOscar Corli, Giovanna Damia, Francesca Galli, et al.
American Journal of Cancer Research|March 23, 2026
Erratum: Molecular determinants of response to PI3K/AKT/mTOR and KRAS pathways inhibitors in NSCLC cell linesAlice Iezzi, Elisa Caiola, Marika Colombo, et al.
Pageof 13